network as a critical mediator of epithelial-stromal interactions during normal mammary ductal development. Target genes for the hedgehog network include the FGF, TGFbeta, and Wnt superfamilies, among others, all of which have known roles in neoplastic progression as well as normal mammary gland development. Indeed, in other tissues, most notably skin, several genes in the hedgehog network have been identified as either oncogenes or tumor suppressor genes, but so far little is known about the involvement of this network in breast cancer. However, we have found that mice heterozygous for a targeted disruption of the Ptc1 gene, which encodes a receptor for the hedgehog family of ligands, develop hyperplasias similar to hyperplasias and ductal carcinomas in situ in the human breast. Regulation of these hyperplasias is hormone dependent, since they revert during pregnancy and lactation but return after involution. Together, these observations suggest the hypothesis that Ptc1 functions as a hormonally-regulated tumor suppressor gene in the breast. To test this hypothesis we propose three specific aims.
In Aim 1 we will determine which function of Ptc1 is responsible for the defects observed by determining the mammary phenotype of Ptc1mes/Ptc1mes and Ptc1HhB/Ptc1HhB virgin mice. Ptc1mes is a newly identified hypomorphic allele of the Ptc1 gene. The protein encoded by this allele lacks most of the C-terminal cytoplasmic tail, and can therefore bind and sequester hedgehog ligand but lacks the ability to inhibit its downstream target SMO. The Ptc1HhB mutation eliminates hedgehog binding but allows PTC1 protein to inhibit SMO constitutively. Also in this aim, we will determine the null phenotype for Ptc1 in the epithelium by creating a mammary-specific conditional knock-out.
In Aim 2 we will determine how hedgehog signaling status is altered by Ptc1 mutations and determine how these mutations affect hormone responses and other tissue-level processes. We will also investigate how hedgehog signaling changes as a function of neoplastic progression in the human breast. Finally, in Aim 3, we will determine whether Ptc1 acts as a mammary tumor suppressor gene by examining tumor formation in crosses with the MMTV-ErbB2 and C3-1-TAg transgenic mouse models of breast cancer.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Program Projects (P01)
Project #
2P01CA030195-22A1
Application #
6989332
Study Section
Subcommittee G - Education (NCI)
Project Start
2004-04-01
Project End
2009-03-31
Budget Start
2004-04-01
Budget End
2005-03-31
Support Year
22
Fiscal Year
2004
Total Cost
$168,617
Indirect Cost
Name
Baylor College of Medicine
Department
Type
DUNS #
051113330
City
Houston
State
TX
Country
United States
Zip Code
77030
Park, Jun Hyoung; Vithayathil, Sajna; Kumar, Santosh et al. (2016) Fatty Acid Oxidation-Driven Src Links Mitochondrial Energy Reprogramming and Oncogenic Properties in Triple-Negative Breast Cancer. Cell Rep 14:2154-2165
Pathiraja, Thushangi N; Nayak, Shweta R; Xi, Yuanxin et al. (2014) Epigenetic reprogramming of HOXC10 in endocrine-resistant breast cancer. Sci Transl Med 6:229ra41
Zhang, Yi; Tseng, Chun-Chih; Tsai, Yuan-Li et al. (2013) Cancer cells resistant to therapy promote cell surface relocalization of GRP78 which complexes with PI3K and enhances PI(3,4,5)P3 production. PLoS One 8:e80071
Machado, Heather L; Kittrell, Frances S; Edwards, David et al. (2013) Separation by cell size enriches for mammary stem cell repopulation activity. Stem Cells Transl Med 2:199-203
Zhang, Xiaomei; Claerhout, Sofie; Prat, Aleix et al. (2013) A renewable tissue resource of phenotypically stable, biologically and ethnically diverse, patient-derived human breast cancer xenograft models. Cancer Res 73:4885-97
Boone, David N; Lee, Adrian V (2012) Targeting the insulin-like growth factor receptor: developing biomarkers from gene expression profiling. Crit Rev Oncog 17:161-73
Casa, Angelo J; Potter, Adam S; Malik, Simeen et al. (2012) Estrogen and insulin-like growth factor-I (IGF-I) independently down-regulate critical repressors of breast cancer growth. Breast Cancer Res Treat 132:61-73
Creighton, Chad J (2012) Molecular classification and drug response prediction in cancer. Curr Drug Targets 13:1488-94
Gutierrez, Carolina; Schiff, Rachel (2011) HER2: biology, detection, and clinical implications. Arch Pathol Lab Med 135:55-62
Wang, Yen-Chao; Morrison, Gladys; Gillihan, Ryan et al. (2011) Different mechanisms for resistance to trastuzumab versus lapatinib in HER2-positive breast cancers--role of estrogen receptor and HER2 reactivation. Breast Cancer Res 13:R121

Showing the most recent 10 out of 260 publications